US Bancorp’s Inhibrx, Inc. Common Stock INBX Stock Holding History

US Bancorp’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-496	Closed	-$17.3K	–	4167
2024 Q1	$17.3K	Hold	496	–	–	﹤0.01%	3150
2023 Q4	$18.8K	Buy	496 +303	+157%	+$6.49K	﹤0.01%	3086
2023 Q3	$3.54K	Buy	193 +128	+197%	+$2.68K	﹤0.01%	3529
2023 Q2	$1.69K	Buy	+65	New	+$1.52K	﹤0.01%	3725
2022 Q4	–	Sell	-123	Closed	-$2K	–	4371
2022 Q3	$2K	Sell	123 -19	-13%	-$343	﹤0.01%	3899
2022 Q2	$2K	Buy	+142	New	+$2.09K	﹤0.01%	3919
2022 Q1	–	Sell	-12	Closed	-$1K	–	4319
2021 Q4	$1K	Buy	+12	New	+$480	﹤0.01%	4076

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp's INBX Position: Q2 2024 in Review

US Bancorp sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 496 shares — an estimated $17.3K sold.

US Bancorp first reported a position in INBX in Q4 2021 and held it in 7 quarters. The position peaked at $18.8K in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

US Bancorp reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
US Bancorp sold 496 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $17.3K.
US Bancorp first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
US Bancorp's Inhibrx, Inc. Common Stock position peaked at $18.8K in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on US Bancorp's 13F filing for Q2 2024, filed 7 Aug 2024.